TP53 and neoplasm: This implies that although TP53 mutations confer a more aggressive tumour phenotype and may drive resistance via other mechanisms, TP53 wild-type tumour cells are more likely to be capable of entering a G0 ‘persistent’ state associated with drug resistance.